NASDAQ : XENE
Xenon Pharmaceuticals Inc. — Key statistics
Healthcare · Biotechnology · Canada
Last price 37.41 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.62B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.62B |
| Enterprise Value | 2.38B |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 96.84M |
| Shares Outstanding | 96.84M |
| Shares Change (YoY) | +10.31% |
| Shares Change (QoQ) | +14.04% |
| Owned by Insiders (%) | 0.17% |
| Owned by Institutions (%) | 101.04% |
| Float | 90.90M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 4,308.09 |
| PB Ratio | 2.91 |
| P/TBV Ratio | 2.92 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 21.02 |
| Quick Ratio | 20.71 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -43.62% |
| Return on Assets (ROA) | -28.02% |
| Return on Invested Capital (ROIC) | -29.18% |
| Return on Capital Employed (ROCE) | -35.31% |
| Weighted Average Cost of Capital (WACC) | 4.70% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.11M |
| Employee Count | 370 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -1.94M |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.08 |
| 52-Week Price Change | -11.56% |
| 50-Day Moving Average | 45.35 |
| 200-Day Moving Average | 52.37 |
| Relative Strength Index (RSI) | 44.28 |
| Average Volume (20 Days) | 1,412,177 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 7.35M |
| Short Previous Month | 6.04M |
| Short % of Shares Out | 7.59% |
| Short % of Float | 8.08% |
| Short Ratio (days to cover) | 2.61 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | -352.49M |
| Operating Income | -441.59M |
| Pretax Income | -411.14M |
| Net Income | -409.20M |
| EBITDA | -439.19M |
| EBIT | -441.59M |
| Earnings Per Share (EPS) | -$4.73 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 930.69M |
| Total Debt | 6.42M |
| Net Cash | 1.24B |
| Net Cash Per Share | $12.79 |
| Equity (Book Value) | 1.24B |
| Book Value Per Share | 12.84 |
| Working Capital | 900.86M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -337.52M |
| Capital Expenditures | -1.01M |
| Depreciation & Amortization | 2.40M |
| Net Borrowing | n/a |
| Free Cash Flow | -338.53M |
| FCF Per Share | -$3.50 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.31% |
| Shareholder Yield | -10.31% |
| Earnings Yield | -12.63% |
| FCF Yield | -9.34% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $71.75 |
| Price Target Difference | 91.79% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 18 |
| Revenue Growth Forecast (3Y) | 209.08% |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | 40.57 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |